A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.

Josep Gamez Matilde Calopa Esteban Muñoz Aileen FerréOscar HuertasKevin McAllisterNúria ReigCatherine Scart-GrèsRaul Insa Boronat Jaime Kulisevsky

Published in: British journal of clinical pharmacology (2022)

Within the limits of this study, the results suggest that SOM3355 reduces chorea in patients with HD and is well-tolerated. Larger studies are necessary to confirm its therapeutic utility as an antichoreic drug. EudraCT number: 2018-000203-16 and ClinicalTrials.gov Identifier: NCT03575676.

Keyphrases

emergency department
drug induced
adverse drug